ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "ANA"

  • Abstract Number: 1346 • 2016 ACR/ARHP Annual Meeting

    Factors That Influence Therapy in Patients with Undifferentiated Connective Tissue Disease

    Diana P. Pena1 and Anca D. Askanase2, 1Rheumatology, Universidad Militar Nueva Granada, Bogotá, Colombia, 2Department of Medicine, Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY

    Background/Purpose: To compare clinical and immunological characteristics in patients with undifferentiated connective tissue disease (UCTD) treated with hydroxycholoroquine (HCQ) in a large academic clinical practice.…
  • Abstract Number: 1769 • 2016 ACR/ARHP Annual Meeting

    Fatigue in Anti-Nuclear Antibody Positive Individuals with Insufficient Criteria to Diagnose a Systemic Autoimmune Rheumatic Disease

    Rawad Nori1, Babak Noamani2, Dennisse Bonilla2, Larissa Lisnevskaia3, Earl Silverman4, Arthur Bookman5, Sindhu R. Johnson1, Carolina Landolt-Marticorena2 and Joan Wither2, 1Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, 2Krembil Research Institute, University Health Network, Toronto, ON, Canada, 3Lakeridge Health Services, Oshawa, ON, Canada, 4University of Toronto, Toronto, ON, Canada, 5Rheumatology, University Health Network, Toronto, ON, Canada

    Background/Purpose:  Fatigue is a common symptom of Systemic Autoimmune Rheumatic Disease (SARD) and has been proposed to result from the elaboration of pro-inflammatory factors in…
  • Abstract Number: 1874 • 2016 ACR/ARHP Annual Meeting

    Low Rate of Progression in Cases of Isolated Raynaud’s Phenomenon Screened By Nailfold Videocapillaroscopy and Antinuclear Antibody Status Supports Negative Predictive Value of These Tests

    Louise Parker1, Kevin Howell2, Voon H. Ong3 and Christopher P.Denton4, 1Centre for Rheumatology and Connective Diseases, UCL Medical School and Royal Free Hosp, London, United Kingdom, 2Institute of Immunity and Transplantation, University College London, Royal Free Campus, London, United Kingdom, 3Rheumatology, UCL Division of Medicine, London, United Kingdom, 4Centre of Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom

    Background/Purpose:   Raynaud’s phenomenon is common but can progress to definite connective tissue disease. We have observed long term follow up of an unselected consecutive…
  • Abstract Number: 2147 • 2016 ACR/ARHP Annual Meeting

    Lack of Pro-Inflammatory Cyto/Chemokines in ANA+ Individuals with Insufficient Criteria for a Diagnosis of Systemic Autoimmune Rheumatic Disease

    Waleed Hafiz1, Nan-Hua Chang2, Babak Noamani3, Dennisse Bonilla3, Larissa Lisnevskaia4, Earl Silverman5, Arthur Bookman6, Sindhu R. Johnson7, Carolina Landolt-Marticorena3 and Joan Wither3, 1Rheumatology, University of Toronto, Toronto, ON, Canada, 2Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, Canada, 3Krembil Research Institute, University Health Network, Toronto, ON, Canada, 4Lakeridge Health Services, Oshawa, ON, Canada, 5Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 6Rheumatology, University Health Network, Toronto, ON, Canada, 7Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada

    Background/Purpose: Patients with Systemic Autoimmune Rheumatic Disease (SARD) often have a prolonged pre-clinical phase during which they are anti-nuclear antibody (ANA) positive but lack clinical…
  • Abstract Number: 2809 • 2016 ACR/ARHP Annual Meeting

    Comparative Analysis of Anti-Nuclear Antibody Testing Using Blinded Replicate Samples Reveals Variability Between Commercial Testing Laboratories

    Marc Chevrier, Jarrat Jordan, Jessica Schreiter and Jacqueline Benson, Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA

    Background/Purpose: Serological positivity defined by presence of anti-nuclear antibodies (ANA) is frequently used in interventional lupus trials as an inclusion criterion and longitudinal biomarker. As such,…
  • Abstract Number: 2814 • 2016 ACR/ARHP Annual Meeting

    Immunofluorescence Pattern and Titer of the Antinuclear Antibody Test Correlate with Disease Activity in Patients with Systemic Lupus Erythematosus

    Mônica Simon Prado1, Alessandra Dellavance2, Sílvia H. Rodrigues3 and Luis Eduardo C. Andrade4,5, 1Rheumatology, Escola Paulista de Medicina, Universidade Federal de São Paulo, UNIFESP-EPM, São Paulo, Brazil, 2Research and Development Department, Fleury Medicine and Health Laboratories, São Paulo, Brazil, 3Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, UNIFESP-EPM, Sao Paulo, Brazil, 4Rheumatology, Escola Paulista de Medicina, Universidade Federal de São Paulo, UNIFESP-EPM, Sao Paulo, Brazil, 5Fleury Health and Medicine, Sao Paulo, Brazil

    Background/Purpose: Antinuclear antibody (ANA) indirect immunofluorescence (IIF) assay on HEp-2 cells (HEp-2-ANA) is an important element for diagnosis and classification of Systemic Lupus Erythematosus (SLE),…
  • Abstract Number: 2918 • 2016 ACR/ARHP Annual Meeting

    The Clinical Relevance of Common ANA Patterns in Systemic Sclerosis

    Ashraf Raslan1, Clifford Stermer2 and Vivien Hsu3, 1Medicine, Rutgers-RWJ Medical School, Jersey City, NJ, 2Medicine, Rutgers-RWJMS, New York, NY, 3Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ

    Background/Purpose: Antinuclear antibody (ANA) test is positive in nearly 95% of patients with systemic sclerosis (SSc) [1]. We aim to identify the clinical relevance of…
  • Abstract Number: 443 • 2016 ACR/ARHP Annual Meeting

    Repetitive Requisition of Antinuclear Antibody Testing (ANA) in Outpatient Multispecialty Clinics in Patients with a Known Positive ANA

    Laura Amorese-O'Connell1, Pinky Vaidya2, Durkhani Mahboob2, Charis Gn3 and Stuart Schwartz4, 1Rheumatology, Brown University, RI hospital, Providence, RI, 2Rheumatology, Roger Williams Medical Center, Providence, RI, 3Internal Medicine, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, 4Brown Medical School, Providence, RI

    Background/Purpose:   Methods:  Retrospective chart review was performed on 598 patients who underwent ANA testing between April 1st, 2015 and March 31st, 2016. Data collected…
  • Abstract Number: 797 • 2016 ACR/ARHP Annual Meeting

    Randomized Clinical Trials of Systemic Lupus Erythematosus: Evaluating Differences in the Enrolled Populations

    Niti Goel1,2, Brandon Barrett3, Ann Duncan4, Margaret-Beth Gallagher1 and Marsha Mackey3, 1Quintiles, Inc., Durham, NC, 2Duke University School of Medicine, Durham, NC, 3Quintiles, Inc., Rockville, MD, 4Quintiles, Inc., Reading, Berkshire, United Kingdom

    Background/Purpose: Background/Purpose: Randomized controlled trials (RCTs) in SLE identify specific populations of interest for eligibility, but still vary in the recruited populations.  These differences may…
  • Abstract Number: 197 • 2015 ACR/ARHP Annual Meeting

    Synergy Between Hematopoietic and Radioresistant Stromal Cells Is Required for Autoimmune Manifestations of Dnase II Deficient Mice

    Rebecca Baum1, Kerstin Nundel1, Sudesh Pawaria1,2, Shruti Sharma1, Patricia Busto1, Tara Robidoux1, Katherine A. Fitzgerald1, Ellen M. Gravallese3 and Ann Marshak-Rothstein1, 1Medicine, University of Massachusetts Medical School, Worcester, MA, 2Department of Medicine, University of Massachusetts Medical School, Worcester, MA, 3Lazare Research Bldg Ste 223, University of Massachusetts Medical School, Worcester, MA

    Background/Purpose: Toll-like receptors (TLRs) dependent on Unc93b1 and cytosolic sensors dependent on STING detect microbial and endogenous nucleic acids to initiate inflammatory responses that resolve…
  • Abstract Number: 273 • 2015 ACR/ARHP Annual Meeting

    Progression Predictive Factors in Patients with Undifferentiated Connective Tissue Disease: A Cohort Study

    Maria Garcia-Gonzalez, Esmeralda Delgado-Frias, Sagrario Bustabad, Ivan Ferraz-Amaro and Beatriz Rodriguez-Lozano, Rheumatology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain

    Background/Purpose: In recent years there has been a growing interest in establishing the concept of Undifferentiated CTD (UCTD) and defining its clinical evolution. Remarkable are…
  • Abstract Number: 564 • 2015 ACR/ARHP Annual Meeting

    Value of Antinuclear Antibodies As a Predictor of Therapeutic Efficacy of Biologics in Rheumatoid Arthritis

    Corina Mogosan1, Luminita Enache1, Denisa Stanciu1, Daniela Opris2, Simona Rednic3, Magda Parvu4, Horatiu Popoviciu5, Ruxandra Ionescu2 and Catalin Codreanu1, 1Rheumatology, 'Dr. Ion Stoia' Clinical Center of Rheumatic Diseases, Bucharest, Romania, 2University of Medicine and Pharmacy “Carol Davila”, Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, 3Rheumatology, Emergency County Clinical Hospital Cluj Napoca, Cluj-Napoca, Romania, 4Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania, 5Rheumatology, Emergency County Hospital, Targu Mures, Romania

    Background/Purpose: Therapeutic target in rheumatoid arthritis (RA) aims at achieving remission or low disease activity. Among the known poor prognostic factors are anti–citrullinated protein antibody…
  • Abstract Number: 740 • 2015 ACR/ARHP Annual Meeting

    The Prevalence of Anti-DFS70 Antibodies in an International Inception Cohort of Systemic Lupus Erythematosus

    May Choi1, John G. Hanly2, Murray Urowitz3,4, Juanita Romero-Diaz5, Caroline Gordon6, Sang-Cheol Bae7, Sasha Bernatsky8, Daniel J Wallace9, Joan T. Merrill10, David A. Isenberg11, Anisur Rahman12, Ellen M. Ginzler13, Paul R. Fortin14, Dafna Gladman15, Jorge Sanchez-Guerrero16, Michelle Petri17, Ian N. Bruce18, Mary Anne Dooley19, Rosalind Ramsey-Goldman20, Cynthia Aranow21, Graciela S. Alarcon22, Kristján Steinsson23, Ola Nived24, Gunnar K. Sturfelt25, Susan Manzi26, Munther Khamashta27, Ronald F. van Vollenhoven28, Asad Zoma29, Guillermo Ruiz-Irastorza30, S. Sam Lim31, Thomas Stoll32, Murat Inanc33, Kenneth C. Kalunian34, Diane L. Kamen35, Peter Maddison36, Christine A. Peschken37, Søren Jacobsen38, Anca Askanase39, Jill P. Buyon40, W. Winn Chatham41, Manuel Ramos-Casals42, Yvan St. Pierre43, Ann E. Clarke44 and Marvin J. Fritzler1, 1Medicine, University of Calgary, Calgary, AB, Canada, 2Rheumatology, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, 3Rheumatology, TWH, Toronto, ON, Canada, 4Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 5Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico city, Mexico, 6Rheumatology (East Wing), Medical School, Birmingham, United Kingdom, 7Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 8Rheum/Clin. Epid., McGill MUHC/RVH, Montreal, QC, Canada, 9Cedars-Sinai Medical Center, West Hollywood, CA, 10Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 11Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, 12Centre for Rheumatology Research, U College of London, London, United Kingdom, 13Medicine/Box 42, SUNY-Downstate, Brooklyn, NY, 14Rheumatology, University of Laval, Quebec, QC, Canada, 15Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 16Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, 17Rheumatology, Johns Hopkins University Hospital, Baltimore, MD, 18Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom, 19UNC Kidney Centre, Chapel Hill, NC, 20Northwestern University Feinberg School of Medicine, Chicago, IL, 21Feinstein Institute for Medical Research, Mahasset, NY, 22Medicine, University of Alabama at Birmingham, Birmingham, AL, 23Rheumatology, Univ. Hospital, Reykjavik, Iceland, 24Rheumatology, Inst of Clinical sciences, Lund, Sweden, 25Department of Rheumatology, Univ Hospital Lund, Lund, Sweden, 26Rheumatology, Allegheny Health Network, Pittsburgh, PA, 27Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, 28Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 29Rheumatology, Hairmyres Hospital, East Kilbride, United Kingdom, 30Universidad del Pais Vasco, Servicio de Medicina Interna, Hospital de Cruces, Bizkaia, Spain, 31Emory University School of Medicine, Atlanta, GA, 32Abteilung Rheumatologie/Rehab, Kantonsspital Schaffhausen, Schaffhausen, Switzerland, 33Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 34Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, 35Medicine, Medical University of South Carolina, Charleston, SC, 36School of Sport, Health and Exercise Sciences, Bangor University, George Building, Bangor, Gwynedd, LL57 2PZ, UK., Bangor, United Kingdom, 37Rheumatology, Univ of Manitoba, Winnipeg, MB, Canada, 38Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 39Columbia University College of Physicians & Surgeons, New York, NY, 40Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 41Medicine/Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 42Department of Autoimmune Diseases, CELLEX-IDIBAPS, Hospital Clínic, Barcelona, Barcelona, Spain, 43Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 44Immunology/Epidemiology, Montreal General Hospital, Montreal, QC, Canada

    Background/Purpose: Autoantibodies to the nuclear autoantigen dense fine speckles 70 (DFS70) are associated with a new paradigm whereby when they are found in isolation (monospecific…
  • Abstract Number: 773 • 2015 ACR/ARHP Annual Meeting

    Clinical Evaluation of Patients with Positive Antibodies to Extractable Nuclear Antigens but Negative ANA

    Megan L. Krause1, Michael Ettore2, Melissa R. Snyder3, Cynthia S. Crowson4 and Kevin G. Moder1, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 3Laboratory Medicine, Mayo Clinic, Rochester, MN, 4Health Sciences Research, Mayo Clinic, Rochester, MN

    Background/Purpose: In the setting of a negative ANA, antibodies to extractable nuclear antigens (ENA) should be correspondingly negative, but alternative clinical scenarios occasionally arise.  This…
  • Abstract Number: 774 • 2015 ACR/ARHP Annual Meeting

    Anti-Nuclear Antibodies Have High Sensitivity for Systemic Lupus Erythematosus: Results of a Systematic Literature Review and Meta-Regression of Diagnostic Data

    Nicolai Leuchten1, Ralph Brinks2, Annika Hoyer3, Monika Schoels4, Martin Aringer1, Sindhu R. Johnson5, David I. Daikh6, Thomas Dorner7, George Bertsias8 and on behalf of the SLE Classification Criteria Steering Committee, 1Medicine III, University Medical Center and Faculty of Medicine at the TU Dresden, Dresden, Germany, 2Hiller Center for Research in Rheumatology, Duesseldorf, Germany, 3Institute for Biometry and Epidemiology, German Diabetes Center, Duesseldorf, Germany, 42nd Department of Medicine, Hietzing Hospital, Vienna, Austria, 5Dept of Rheumatology, Toronto Western and Mt. Sinai Hospitals, University of Toronto, Toronto, ON, Canada, 6Rheumatology, UCSF/VA Medical Center, San Francisco, CA, 7Charité University Medicine Berlin, Berlin, Germany, 8Rheumatology, Clinical Immunology, and Allergy, University of Crete, Heraklion, Greece

    Background/Purpose: EULAR and ACR have jointly funded a project to improve existing SLE classification criteria, aiming at earlier and more accurate classification of the disease.…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology